insights_auto
Kodėl „HBMN“ sumažėjo 2,52%?
Įsigilintichevron_right
HBMN:SWX
HBM Healthcare Investments AG
213,00 CHF
arrow_downward
−2,52%(−5,50) 1 D.
11-20, 17:30:23 GMT+1 · CHF
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „HBMN“ įžvalgos...
Atidaryti
220,00 CHF
Aukšta
220,00 CHF
Žema
212,00 CHF
Rinkos kapitalizacija
1,41 mlrd.
Vid. kiekis
5,99 tūkst.
Apimtis
4,98 tūkst.
Dividendas
4,23 %
Ketvirčio dividendai
2,25 CHF
Teisių į dividendus praradimo data
2026-06-17
P/E santykis
4,00
52 sav. aukšta
258,00 CHF
52 sav. žema
198,60 CHF
Pajamos iš vienos akcijos
53,19 CHF
Neapmokėtos akcijos
6,62 mln.
Atidaryti
220,00 CHF
Aukšta
220,00 CHF
Žema
212,00 CHF
Rinkos kapitalizacija
1,41 mlrd.
Vid. kiekis
5,99 tūkst.
Apimtis
4,98 tūkst.
Dividendas
4,23 %
Ketvirčio dividendai
2,25 CHF
Teisių į dividendus praradimo data
2026-06-17
P/E santykis
4,00
52 sav. aukšta
258,00 CHF
52 sav. žema
198,60 CHF
Pajamos iš vienos akcijos
53,19 CHF
Neapmokėtos akcijos
6,62 mln.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
WSJ
·
prieš 1 dieną
Dow, S&P 500 Poised to Close at a Correction
Beinsure
·
prieš 11 valandų
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
Trefis
·
prieš 20 valandų
S&P 500 Movers | Winners: GPN, GIS, MKC | Losers: BE, NVDA, LITE
The Motley Fool
·
prieš 10 valandų
The S&P 500 Heads Into Thanksgiving Below Its Peak. Here's How the Holiday Week Has Usually Gone Since 1950.
Profilis
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Apie „HBM Healthcare Investments AG“
Generalinis direktorius-
Darbuotojai-
Įkurta2001-07-12
Pagrindinė būstinėCugas, Cugas, Šveicarija
SektoriusFinancials
Pramonės sritis-
Svetainėhbmhealthcare.com